Quantify the global burden and trajectory of antimicrobial resistance, document the economic costs of inaction, and assess the time window remaining for systemic intervention before AMR becomes an existential threat to modern medicine.

Analysis of WHO Global Report on Antimicrobial Surveillance 2024, RAND Corporation economic burden studies, and CDC antibiotic resistance threat assessments across 180 countries. Comparative analysis of resistance prevalence across pathogens, geographies, and antimicrobial classes. Projection modeling of resistance spread under current trajectory vs. intervention scenarios through 2050.

95 million deaths are associated with AMR — totaling nearly 6 million excess deaths per year. Without intervention, AMR could cause 10 million deaths annually by 2050 and reduce global GDP by $100 trillion cumulatively.

The most dangerous resistance patterns — carbapenem-resistant Enterobacteriaceae (CRE), extensively drug-resistant (XDR) tuberculosis, and methicillin-resistant Staphylococcus aureus (MRSA) — are spreading faster than any public health intervention is being deployed.

Critically, the window for action is closing: once a resistance mechanism becomes prevalent in a population, it cannot be reversed, only managed. Developing countries bear 73% of the disease burden but have no infrastructure to track or respond to resistance emergence.